Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Malka

Showing results (1-10 of 192) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2022
Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer?Julien Edeline, David Malka
The Lancet. Gastroenterology & Hepatology|June 13, 2024
Nanoliposomal irinotecan in advanced biliary tract cancersDavid Malka, Raphaël Colle
Gastroenterologie Clinique Et Biologique|April 22, 2003
[Can the natural history of diabetes be changed in chronic pancreatitis?]David Malka, Pascal Hammel
Journal of Gastrointestinal Oncology|March 12, 2026
Antiangiogenic therapy for advanced biliary tract cancers: promising or illusory?Raphael Colle, David Malka
The Lancet. Oncology|March 30, 2019
Adjuvant capecitabine in biliary tract cancer: a standard option?David Malka, Julien Edeline
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2022
Reply to M. Salati et alJean Marc Phelip, David Malka
The New England Journal of Medicine|March 21, 2019
FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer. ReplyDavid Malka, Florence Castan, Thierry Conroy
The Lancet. Oncology|December 4, 2010
Biliary cancers, chemotherapy, and cetuximabDavid Malka, Valérie Boige, Michel Ducreux
Bulletin Du Cancer|January 3, 2006
[Therapeutic strategies using VEGF inhibitors in colorectal cancer]Valérie Boige, David Malka, Michel Ducreux
Onkologie|February 1, 2007
CA 19-9 and pancreatic carcinoma, a revival?Michel Ducreux, Valérie Boige, David Malka
Pageof 20

Showing results (1-10 of 192) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2022
Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer?Julien Edeline, David Malka
The Lancet. Gastroenterology & Hepatology|June 13, 2024
Nanoliposomal irinotecan in advanced biliary tract cancersDavid Malka, Raphaël Colle
Gastroenterologie Clinique Et Biologique|April 22, 2003
[Can the natural history of diabetes be changed in chronic pancreatitis?]David Malka, Pascal Hammel
Journal of Gastrointestinal Oncology|March 12, 2026
Antiangiogenic therapy for advanced biliary tract cancers: promising or illusory?Raphael Colle, David Malka
The Lancet. Oncology|March 30, 2019
Adjuvant capecitabine in biliary tract cancer: a standard option?David Malka, Julien Edeline
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2022
Reply to M. Salati et alJean Marc Phelip, David Malka
The New England Journal of Medicine|March 21, 2019
FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer. ReplyDavid Malka, Florence Castan, Thierry Conroy
The Lancet. Oncology|December 4, 2010
Biliary cancers, chemotherapy, and cetuximabDavid Malka, Valérie Boige, Michel Ducreux
Bulletin Du Cancer|January 3, 2006
[Therapeutic strategies using VEGF inhibitors in colorectal cancer]Valérie Boige, David Malka, Michel Ducreux
Onkologie|February 1, 2007
CA 19-9 and pancreatic carcinoma, a revival?Michel Ducreux, Valérie Boige, David Malka
Pageof 20